International journal of molecular sciences, 2019-07, Vol.20 (14), p.3383
2019
Details
- Autor(en) / Beteiligte
- Titel
- Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer
- Ist Teil von
- International journal of molecular sciences, 2019-07, Vol.20 (14), p.3383
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2019
- Link zum Volltext
- Quelle
- Electronic Journals Library - Freely accessible e-journals
- Beschreibungen/Notizen
- Acquired paclitaxel (PTX) resistance limits its effectiveness and results in advanced cancer progression. This review investigated whether the inhibition of phosphatidylinositol 3-kinase (PI3K) signaling overcomes paclitaxel resistance in cervical cancer. It was established paclitaxel-resistant cell lines (PTX-R ME180/PTX-R HeLa) and determined the combination index for paclitaxel and PI3K inhibitors (BYL-719/ LY294002) by tetrazolium dye assay. Flow cytometry was used to detect the cell cycle and apoptosis. Migration and invasion were explored by wound healing and transwell assays. Genes related to multiple pathways were assessed by a western blot. It was found that the PI3K pathway was significantly activated in paclitaxel-resistant HeLa and ME180 cells compared to parental cells. PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression. Moreover, combination therapy significantly enhanced drug sensitivity and apoptosis through the activation of Bax, and cleavage of poly-(ADP-ribose) polymerase compared with paclitaxel alone. In addition, PI3K inhibition also suppressed tumor migration and invasion by targeting β-catenin and matrix metalloproteinase-2/9. The authors suggest that the combination of a PI3K inhibitor with paclitaxel may enhance antitumor activity through a cascade of PI3K signaling events.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1422-0067, 1661-6596eISSN: 1422-0067DOI: 10.3390/ijms20143383Titel-ID: cdi_doaj_primary_oai_doaj_org_article_29e3e6465c734785a19475f0cc2152a8
- Format
- –
- Schlagworte
- 1-Phosphatidylinositol 3-kinase, Antineoplastic Agents - pharmacology, Antitumor activity, Apoptosis - drug effects, Apoptosis - genetics, Cancer therapies, Cell cycle, Cell Cycle - drug effects, Cell Cycle - genetics, Cell Line, Tumor, Cervical cancer, Cervix, Chemotherapy, Class I Phosphatidylinositol 3-Kinases - genetics, Clinical trials, combination therapy, DNA Damage, Drug Resistance, Neoplasm - drug effects, Drug Resistance, Neoplasm - genetics, Drug Synergism, Enzyme Inhibitors - pharmacology, Female, Gene expression, Genetic Variation, Genomes, Human papillomavirus, Humans, Inhibitors, invasion, Kinases, Medical prognosis, Metastasis, Mutation, Mutation rates, Paclitaxel, Paclitaxel - pharmacology, paclitaxel resistance, Pharmacokinetics, Phosphatidylinositol 3-Kinase - genetics, Phosphatidylinositol 3-Kinase - metabolism, PI3K inhibitor, Proto-Oncogene Proteins c-akt - metabolism, Sensitivity, Signal processing, Signal transduction, Signal Transduction - drug effects, Signaling, Toxicity, Tumors, Uterine Cervical Neoplasms - drug therapy, Uterine Cervical Neoplasms - metabolism